Prior Decompensation Flags High Mortality Risk After Variceal Bleeding

This individual participant data meta-analysis identifies a subgroup of variceal hemorrhage patients on standard NSBB plus ligation prophylaxis who remain at substantially elevated death risk and may warrant escalated therapy.

non-selective beta-blockersendoscopic variceal ligationTIPSvariceal hemorrhagecirrhosisportal hypertensiondecompensationasciteshepatic encephalopathyIPD meta-analysisprognosis Clinical Pharmacy Practice

Background Information

Prior liver decompensation doubles mortality risk after variceal bleeding.

Identifying high-risk patients after variceal hemorrhage (VH) can improve treatment strategies and patient outcomes. Patients with prior decompensation had significantly higher two-year mortality (25.1% vs 13.5%, p<0.0001) despite receiving recommended therapy. Prior decompensation signals increased mortality risk, suggesting the need to explore early transjugular intrahepatic portosystemic shunt (TIPS) in this population. Patients with prior decompensation face higher mortality risk after VH despite standard therapy.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Turco L, La Mura V, Olivas P, Rudler M, Villanueva C, Hernandez-Gea V, Han G, Chirapongsathorn S, Shalimar, Bucsics T, Palazon JM, Reiberger T, Thabut D, Garcia-Guix M, Luo X, Sharma S, Agarwal S, Bosch J, Garcia-Pagan JC, D'Amico G, Garcia-Tsao G

Citation: Turco L, La Mura V, Olivas P, et al. Prior decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An IPD Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2026. doi:10.1016/j.cgh.2026.07.007

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →